Davide Capodanno
EuroIntervention Editor-in-Chief
Latest contributions
EuroIntervention Achieves Record Impact Factor of 9.5
25 Jun 2025
Toulouse, FRANCE: Clarivate, publisher of the Journal Citation Reports (JCR) has announced the new Impact Factor for EuroIntervention of 9.5, putting it in the top percentile of academic publications published today.
Celebrating 20 years of EuroIntervention!
22 May 2025
According to Editor-in-Chief, Davide Capodanno, EuroIntervention marks this milestone by continuing its upward trajectory, blending cutting-edge and traditional elements to bring the latest data to its readers faster than ever before.
Author
Pharmacotherapy coronary interventions: new insights
22 May 2025 – From EuroPCR 2025
Stay abreast of new insights in pharmacotherapy for coronary interventions with a focus on optimizing patient outcomes. Topics include ticagrelor monotherapy in chronic coronary syndrome post-PCI, analysis of multiple events in high bleeding risk patients from the MASTER DAPT trial, effects of beta-blocker interruption in MI...
If I can’t stent it, should I care? Unmasking hidden atherosclerosis through novel imaging techniques
22 May 2025 – From EuroPCR 2025
Unveil the potential of novel imaging techniques in identifying hidden atherosclerosis and silent inflammation. This session discusses the role of perivascular adipose tissue in plaque development, highlights advances in early inflammation detection, and explores clinical management of patients with athero-inflammation beyond traditional stenting options.
Understanding research: insights from a groundbreaking study
22 May 2025 – From EuroPCR 2025
Enhance your understanding of contemporary research in PCI versus CABG with this session. Learn foundational research principles, latest study findings, and how to translate evidence into clinical practice to improve patient communication and outcomes, bridging the gap between research and everyday cardiology care.
What an interventional cardiologist should know about anti-thrombotics
22 May 2025 – From EuroPCR 2025
This session provides comprehensive knowledge on anti-thrombotic management for interventional cardiologists, emphasizing effective inhibition during acute STEMI, latest evidence implementation for high bleeding risk patients, and customization of dual antiplatelet therapy in patients with high thrombotic and low bleeding risks through clinical cases and evidence-based recommendations.
From evidence to practice: solving complex cases with EuroIntervention
22 May 2025 – From EuroPCR 2025
Translate evidence into clinical practice with this session focusing on complex case analyses supported by EuroIntervention resources. Experience detailed presentations of challenging PCI, intracoronary imaging, coronary physiology, and TAVI cases, each followed by evidence-based solutions provided through EuroIntervention. Enhance your decision-making skills by integrating guidelines and...
Academic Research Consortium initiative on left atrial appendage closure – standardising definitions and endpoints to move forward
21 May 2025
Philippe Garot describes the EuroPCR 2025 session on left atrial appendage closure (LAAC), which offers a preview of the upcoming new consensus document developed by the Academic Research Consortium.
Author
Major Late-Breaking Trials from EuroPCR 2025
21 May 2025 – From EuroPCR 2025
Discover major late-breaking trials from EuroPCR 2025 in this session presenting pivotal study data. Highlights include meta-analyses from the PROTECTED TAVR and BHF PROTECT-TAVI studies, angiography versus physiology-guided PCI during TAVI (FAITAVI trial), and novel antiplatelet strategies following drug-coated stent implantation in acute coronary syndrome, with...
Academic Research Consortium on LAA closure
21 May 2025 – From EuroPCR 2025
Gain comprehensive understanding of the Academic Research Consortium's achievements in left atrial appendage (LAA) closure. Learn how standardized endpoints are streamlined for randomized controlled trials and how collaborative efforts homogenize definitions to advance clinical research.
TAVI for asymptomatic aortic stenosis after EARLY TAVI - TAVI and coronary artery disease after NOTION-3
21 May 2025 – From EuroPCR 2025
Critically assess the clinical implications of the EARLY TAVI and NOTION-3 trials with a focus on asymptomatic aortic stenosis and concomitant coronary artery disease. This session integrates recent evidence into patient-centered care pathways, offering case-based insights for optimizing timing and management strategies in TAVI patients.
Optimal management of high bleeding risk patient with multivessel disease
21 May 2025 – From EuroPCR 2025
This session offers a comprehensive overview of the management of high bleeding risk (HBR) patients with multivessel disease. Through expert discussion and a live case demonstration featuring a complex elderly patient, it highlights how intracoronary imaging and physiology can guide procedural decisions and improve outcomes in this...
Align for the future with the Myval Octapro transcatheter heart valve series
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a practical and evidence-based update on the Myval Octapro THV. Learn step-by-step techniques for valve-in-valve TAVI using the OctaAlign approach, and understand how intermediate sizes and precise deployment contribute to optimised hemodynamics and long-term durability.
Clinical insights are backed by key data...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
EuroIntervention Journal: 20 years of excellence
25 Feb 2025
Join the PCR community as we commemorate a big year for EuroIntervention!
In this video, your peers share why they read EuroIntervention and how it impacts their daily practice.
Author
Author
Author
Author
Author
Author
Author
Author
Author
Author
Author
Best of science and education in cardiovascular interventional medicine in 2024
16 Dec 2024
Dear Colleagues, dear PCR Companions,
As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.
2024 was a record year...
Insights from the top late-breaking trials at PCR London Valves 2024
24 Nov 2024 – From PCR London Valves 2024
Looking to stay ahead in transcatheter valve therapies? Don't miss out this video showcasing the most impactful late-breaking trials from PCR London Valves 2024.
Discover pivotal findings, including one-year results comparing two balloon-expandable TAVI valves, outcomes of the TRISCEND II trial for tricuspid regurgitation and groundbreaking insights...
Pre-emptive TAVI for asymptomatic severe aortic stenosis - From headlines to clinical practice
24 Nov 2024 – From PCR London Valves 2024
Is early TAVI the right choice for your asymptomatic patients with severe aortic stenosis? In this video, we break down the latest clinical trials, including EARLY TAVR and EVOLVED, to help you navigate the complex decision-making process.
Find out what these studies really tell us about the...
EuroPCR 2024 Closing Ceremony
17 May 2024 – From EuroPCR 2024
This session is the closing ceremony for EuroPCR 2024. It includes the presentation of the PCR's Got Talent competition, a discussion on the new developments in PCI such as angiography-based computational physiology, AI, and vulnerable plaque intervention, as well as highlights from the congress. The ceremony...
Scientific highlights, clinical trial updates and key learnings from EuroPCR 2024
17 May 2024 – From EuroPCR 2024
Davide Capodanno presents notable trial updates, coronary devices, and key takeaways from EuroPCR 2024. Highlights include the SOLVE-TAVI and IDEAL-LM trials at 5 years, BIOADAPTOR at 2 years, advancements in drug-coated balloons and DES, as well as insights from REC-CAGEFREE II, LANDMARK, and NOTION-2.
References
- SOLVE-TAVI: Feistritzer HJ, et al....
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
Align for the future with next-generation balloon expandable THV technology
15 May 2024 – From EuroPCR 2024
In this session, explore the next-generation balloon-expandable Myval Octacor THV, focusing on its key features, procedural impact, and potential clinical benefits. Understand the procedural steps for planning and implanting it, especially for intermediate and extra-large sizes, using the Octalign technique. Learn about the unmet clinical need...
Complex PCI in ACS patient with high bleeding risk: optimise the strategy
15 May 2024 – From EuroPCR 2024
Watch this session for insights into managing acute coronary syndrome patients with multivessel disease, updates on treatment approaches, comparing FULL RESVAC with previous trials like COMPLETE or FIRE, for example, and information on ongoing trials such as FRAMI-AMI 2 and 3. Explore the LIVE case presentation...
These EuroIntervention papers changed my practice!
15 May 2024 – From EuroPCR 2024
Targeting inflammation in AMI: a debate
14 May 2024 – From EuroPCR 2024
Watch this session to explore inflammation's role in AMI, from atherosclerosis to post-infarct remodeling. Find out more about IL-6's significance in future MACE risk and cardiac status deterioration post-AMI, and delve into targeting inflammation via IL-6, evaluating short and long-term impacts.
Understanding how to use evidence in clinical practice
14 May 2024 – From EuroPCR 2024
This session focuses on understanding how to apply the latest evidence and clinical guidelines in daily practice for Non-Interventional Cardiologists (NAPs). It covers the influence of patient-reported outcomes on cardiovascular clinical practices, the translation of the 2023 ACS clinical guidelines into NAP's practice, the impact of...
Coronary interventions: Highlights of EuroPCR 2024
16 May 2024 – From EuroPCR 2024
In this video, Thomas Cuisset and Davide Capodanno discuss with Dejan Milasinovic key moments in coronary intervention at EuroPCR 2024. They highlight innovations in intravascular imaging education, featuring the Imaging Learning Center and its hands-on workstations, and key studies like DOCTOR-LM, following in the footsteps of OCTOBER or BIFURCATION. Educating...
Bioadaptor RCT 2 years: could we further improve long-term CAD outcomes vs DES?
14 May 2024 – From EuroPCR 2024
Follow this exchange between Antonio Colombo, Stefan Verheye, and Davide Capodanno as they discuss the past, present, and future of drug-eluting stents. They address the current limitations, emphasizing the issue of vessel caging, and suggest improvements, particularly highlighting the new Bioadaptor with uncaging bioresorbable elements that...
"My Take on OCT Trials" by Davide Capodanno: CRT 2024
19 Mar 2024
View a series of commented slides illustrating major takeaways from a network meta-analysis of Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography in the Guidance of Percutaneous Coronary Intervention. These slides and comments were originally shared via Twitter upon the occasion of the 2024 Cardiovascular Research...
Author
